Hemophilia A Recent News
Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression
BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate
Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
Serious Adverse Event Triggers FDA Clinical Hold On Sigilon Therapeutics' Hemophilia A Trial, Shares Drop
EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy
Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit
Newly Launched Centessa Pharmaceuticals Plans $100M Debut On NASDAQ
BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US
Baird Buying Ultragenyx And BioMarin